➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
Dow
Boehringer Ingelheim
Baxter

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

AZILECT Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Azilect patents expire, and what generic alternatives are available?

Azilect is a drug marketed by Teva and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in AZILECT is rasagiline mesylate. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.

Summary for AZILECT
Drug patent expirations by year for AZILECT
Drug Prices for AZILECT

See drug prices for AZILECT

Recent Clinical Trials for AZILECT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of FloridaPhase 2
National Institute of Neurological Disorders and Stroke (NINDS)Phase 2
Thomas GuttusoN/A

See all AZILECT clinical trials

Pharmacology for AZILECT

US Patents and Regulatory Information for AZILECT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No   Try Before You Buy   Try Before You Buy Y Y   Try Before You Buy
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 AB RX Yes Yes   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 AB RX Yes No   Try Before You Buy   Try Before You Buy Y   Try Before You Buy
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 AB RX Yes Yes   Try Before You Buy   Try Before You Buy Y Y   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AZILECT

Supplementary Protection Certificates for AZILECT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0812190 C300205 Netherlands   Try Before You Buy PRODUCT NAME: RASAGILINE, DESGEWENST IN DE VORM VAN EENFARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/04/304/001 T/M 007 20050221
0812190 SPC/GB05/042 United Kingdom   Try Before You Buy PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221
0812190 91191 Luxembourg   Try Before You Buy 91191, EXPIRES: 20191012
0436492 91195 Luxembourg   Try Before You Buy 91195, EXPIRES: 20160102
0812190 SPC024/2005 Ireland   Try Before You Buy SPC024/2005, 20060725, EXPIRES: 20191011
0812190 05C0033 France   Try Before You Buy PRODUCT NAME: RASAGILINE; NAT. REGISTRATION NO/DATE: EU/1/04/304/001-007 20050221; FIRST REGISTRATION: EU/1/4/304/001-007 20050221
0812190 C00812190/01 Switzerland   Try Before You Buy FORMER OWNER: TEVA PHARMACEUTICAL INDUSTRIES, LTD., IL
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Colorcon
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.